Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares Silver Trust (SLV) Price & Performance

Regeneron Pharmaceuticals IncTrade
iShares Silver TrustTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs iShares Silver Trust — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while iShares Silver Trust trades at $61.05. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while iShares Silver Trust pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.

REGNSLV
Market Cap
$83.43B
Sector
Health
52-Week High
$852.03$105.57
52-Week Low
$555.51$37.41
Enterprise Value
$78.14B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

iShares Silver Trust

SLV, the iShares Silver Trust ETF, trades at $59.37, down 0.75% on the day, with a bearish technical signal driven by moving averages. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver. Recent news highlights silver's volatility amid Fed policy uncertainty and geopolitical tensions, with institutional buying noted in Q2 2026 filings.

Outlook remains mixed: silver's structural deficit supports prices, but Fed rate risks and dollar fluctuations pose headwinds. Investors face volatility from industrial demand shifts and inflation data, with technical resistance near $60–$61 capping near-term upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About iShares Silver Trust

The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.

Read more on SLV